tetano
Editor, Senior Moderator
Vaccine
. 2023 Aug 9;S0264-410X(23)00941-6.
doi: 10.1016/j.vaccine.2023.08.009. Online ahead of print. An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection
Yoshikazu Honda-Okubo[SUP] 1 [/SUP], E Bart Tarbet[SUP] 2 [/SUP], Brett L Hurst[SUP] 2 [/SUP], Nikolai Petrovsky[SUP] 3 [/SUP]
Affiliations
There is a major unmet need for strategies to improve the immunogenicity of vaccines to protect against highly pathogenic avian influenza strains with pandemic potential. This study tested the ability of adjuvants based on delta inulin (Advax™) alone or combined with a TLR9 agonist (Advax-CpG™) to enhance the immunogenicity of recombinant H5 hemagglutinin antigen expressed in insect cells (rH5HA) to protect mice against lethal influenza infection. The Advax-adjuvanted rH5HA induced high serum hemagglutination inhibition activity, as well as Th1 and Th2 cytokine secreting CD4 and CD8 T cells. Immunization protected mice against a lethal heterosubtypic H5N1 virus challenge. Mice immunized with an Advax-adjuvanted rHA2 stem antigen prepared by enzymatic cleavage of rH5HA produced serum antibodies devoid of hemagglutination inhibition activity, but these anti-HA2 antibodies were nevertheless able to transfer protection against lethal H1N1 or H3N2 infections to naïve mice. We hypothesize that the enhanced protection afforded by Advax-adjuvanted rH5HA may be mediated by the combination of neutralizing antibodies directed at the HA head, anti-HA2 stem antibodies plus memory CD4 + and CD8 + T cells. This outcome supports further development of the Advax-adjuvanted rH5 pandemic influenza vaccine platform.
Keywords: Adjuvant; Advax-CpG; Avian; Delta inulin; Influenza; Pandemic; Vaccine.
. 2023 Aug 9;S0264-410X(23)00941-6.
doi: 10.1016/j.vaccine.2023.08.009. Online ahead of print. An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection
Yoshikazu Honda-Okubo[SUP] 1 [/SUP], E Bart Tarbet[SUP] 2 [/SUP], Brett L Hurst[SUP] 2 [/SUP], Nikolai Petrovsky[SUP] 3 [/SUP]
Affiliations
- PMID: 37567799
- DOI: 10.1016/j.vaccine.2023.08.009
There is a major unmet need for strategies to improve the immunogenicity of vaccines to protect against highly pathogenic avian influenza strains with pandemic potential. This study tested the ability of adjuvants based on delta inulin (Advax™) alone or combined with a TLR9 agonist (Advax-CpG™) to enhance the immunogenicity of recombinant H5 hemagglutinin antigen expressed in insect cells (rH5HA) to protect mice against lethal influenza infection. The Advax-adjuvanted rH5HA induced high serum hemagglutination inhibition activity, as well as Th1 and Th2 cytokine secreting CD4 and CD8 T cells. Immunization protected mice against a lethal heterosubtypic H5N1 virus challenge. Mice immunized with an Advax-adjuvanted rHA2 stem antigen prepared by enzymatic cleavage of rH5HA produced serum antibodies devoid of hemagglutination inhibition activity, but these anti-HA2 antibodies were nevertheless able to transfer protection against lethal H1N1 or H3N2 infections to naïve mice. We hypothesize that the enhanced protection afforded by Advax-adjuvanted rH5HA may be mediated by the combination of neutralizing antibodies directed at the HA head, anti-HA2 stem antibodies plus memory CD4 + and CD8 + T cells. This outcome supports further development of the Advax-adjuvanted rH5 pandemic influenza vaccine platform.
Keywords: Adjuvant; Advax-CpG; Avian; Delta inulin; Influenza; Pandemic; Vaccine.